Literature DB >> 25047222

Litigation seeking access to data from ongoing clinical trials: a threat to clinical research.

Walter N Kernan1, Catherine M Viscoli1, Mathew C Varughese2.   

Abstract

Researchers conducting randomized clinical trials may find themselves subject to legal subpoenas for interim data. When a subpoena demands premature disclosure of unblinded data, there is potential for damage to the scientific integrity and reputation of the on-going trial. We describe herein general issues raised by subpoenas for trial data and the particular case of a 2012 subpoena served on investigators from Yale University who were successful in winning reprieve from Connecticut Superior Court.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25047222      PMCID: PMC5758866          DOI: 10.1001/jamainternmed.2014.3248

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  9 in total

1.  Preparing for responsible sharing of clinical trial data.

Authors:  Michelle M Mello; Jeffrey K Francer; Marc Wilenzick; Patricia Teden; Barbara E Bierer; Mark Barnes
Journal:  N Engl J Med       Date:  2013-10-21       Impact factor: 91.245

2.  The biomedical researcher and subpoenas: judicial protection of confidential medical data.

Authors:  A R Holder
Journal:  Am J Law Med       Date:  1986

3.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Authors:  John A Dormandy; Bernard Charbonnel; David J A Eckland; Erland Erdmann; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene; Meng H Tan; Pierre J Lefèbvre; Gordon D Murray; Eberhard Standl; Robert G Wilcox; Lars Wilhelmsen; John Betteridge; Kåre Birkeland; Alain Golay; Robert J Heine; László Korányi; Markku Laakso; Marián Mokán; Antanas Norkus; Valdis Pirags; Toomas Podar; André Scheen; Werner Scherbaum; Guntram Schernthaner; Ole Schmitz; Jan Skrha; Ulf Smith; Jan Taton
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

4.  Pioglitazone for diabetes prevention in impaired glucose tolerance.

Authors:  Ralph A DeFronzo; Devjit Tripathy; Dawn C Schwenke; MaryAnn Banerji; George A Bray; Thomas A Buchanan; Stephen C Clement; Robert R Henry; Howard N Hodis; Abbas E Kitabchi; Wendy J Mack; Sunder Mudaliar; Robert E Ratner; Ken Williams; Frankie B Stentz; Nicolas Musi; Peter D Reaven
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

5.  Calcium plus vitamin D supplementation and the risk of fractures.

Authors:  Rebecca D Jackson; Andrea Z LaCroix; Margery Gass; Robert B Wallace; John Robbins; Cora E Lewis; Tamsen Bassford; Shirley A A Beresford; Henry R Black; Patricia Blanchette; Denise E Bonds; Robert L Brunner; Robert G Brzyski; Bette Caan; Jane A Cauley; Rowan T Chlebowski; Steven R Cummings; Iris Granek; Jennifer Hays; Gerardo Heiss; Susan L Hendrix; Barbara V Howard; Judith Hsia; F Allan Hubbell; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis H Kuller; Robert D Langer; Norman L Lasser; Marian C Limacher; Shari Ludlam; JoAnn E Manson; Karen L Margolis; Joan McGowan; Judith K Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Gloria E Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Evelyn Whitlock; Garnet L Anderson; Annlouise R Assaf; David Barad
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

6.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

7.  One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

Authors:  Markolf Hanefeld; Paolo Brunetti; Guntram H Schernthaner; David R Matthews; Bernard H Charbonnel
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

8.  Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

Authors:  James D Lewis; Assiamira Ferrara; Tiffany Peng; Monique Hedderson; Warren B Bilker; Charles P Quesenberry; David J Vaughn; Lisa Nessel; Joseph Selby; Brian L Strom
Journal:  Diabetes Care       Date:  2011-04       Impact factor: 19.112

9.  Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.

Authors:  A Neumann; A Weill; P Ricordeau; J P Fagot; F Alla; H Allemand
Journal:  Diabetologia       Date:  2012-03-31       Impact factor: 10.122

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.